drugset / Trial / NCT04640402
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)
Phase 2
Completed
960 enrolled
Jiangsu Province Centers for Disease Control and Prevention
West China Hospital · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (Sf9 cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with different immunization procedures (0, 21 days and 0, 14, 28 days) and doses (20μg/40μg).
Timeline
- Start
- 2020-11-17
- Primary completion
- 2021-02-18
- Completion
- 2021-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant COVID-19 vaccine (Sf9 cells) | Vaccine | 20 ug | — |
| Subject | Recombinant COVID-19 vaccine (Sf9 cells) | Vaccine | 40 ug | — |